Therapeutic outcomes of papillary thyroid cancer patients in different risk groups

Oncology

Volumn 80, Issue 1-2, 2011, Pages 123-129

  Huang, Bie Yu ^a   Lin, Jen Der ^a,c   Chao, Tzu Chieh ^b   Lin, Kun Ju ^b   Hseuh, Chuen ^b   Tsang, Ngan Ming ^b  

^a Division of Endocrinology and Metabolism   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

131I therapy; Cancer related mortality; Insular pattern; Thyroglobulin

Indexed keywords

IODINE 131;

ABLATION THERAPY; ADULT; ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHOCYTIC THYROIDITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SEX RATIO; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY SCINTISCANNING;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE MORAL JUDGMENT; RISK FACTORS; SEX FACTORS; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR BURDEN;

EID: 79958765027     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328912     Document Type: Article

References (32)

1. Wada N, Hasegawa S, Masudo Y, et al: 2007 Clinical outcome by AMES risk definition in Japanese differentiated thyroid carcinoma patients. Asian J Surg 2007; 30: 102-107.
2. Lin JD, Chen ST, Hsueh C, Choa TC: A 29-year retrospective review of papillary thyroid cancer in one institution. Thyroid 2007; 17: 535-541. (Pubitemid 47068116)
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803. (Pubitemid 43997716)
4. Cooper DS, Doherty G.M, Haugen BR, et al: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142.
5. Puxeddu E, Filetti S: The 2009 American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus-to evidence-based practice. Thyroid 2009; 19: 1145-1147.
6. Sobin LH, Wittekind C (eds): TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002, pp 52-56.
7. Gharib H, Papini E, Paschke R: Thyroid nodules: a review of current guidelines, practices, and prospects. Eur J Endocrinol 2008; 159: 493-505.
8. Verburg FA, Stokkel MP, Düren C, et al: No survival difference after successful (131)I ablation between patients with initially lowrisk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 276-283.
9. Delellis RA, Lloyd RV, Heitx PU, Eng C (eds): World Health Organization of Tumours: Pathology and Genetics-Tumors of Endocrine Organs. Lyon, IARC, 2004, pp 73-76.
10. Lin JD, Chao TC, Hsueh C, Kuo SF: High recurrent rate of multi-centric papillary thyroid carcinoma. Ann Surg Oncol 2009; 16: 2609-2616.
11. Chao TC, Lin JD, Chen MF: Insular carcinoma: infrequent subtype of thyroid cancer with aggressive clinical course. World J Surg 2004; 28: 393-396.
12. Ghossein RA, Leboeuf R, Patel KN, et al: Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 2007; 17: 655-661. (Pubitemid 47311555)
13. Asioli S, Erickson LA, Sebo TJ, et al: Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma - a clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol 2010; 34: 44-52.
14. Zhang DD, Zhou XH, Freeman DH, Freeman JL: A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets. Stat Med 2002; 21: 701-715. (Pubitemid 34467243)
15. Freschi G, Landi L, Castagnoli A, Taddei A, Bechi P, Bucciarelli G: Advanced thyroid carcinoma: an experience of 385 cases. Eur J Surg Oncol 2006; 32: 577-582.
16. Sanders LE, Cady B: Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998; 133: 419-425. (Pubitemid 28193527)
17. Zanotti-Fregonara P, Khoury A, Duron F, et al: Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging 2007; 34: 541-546. (Pubitemid 46426998)
18. Kim TY, Kim WB, Kim ES, et al: Serum thyroglobulin levels at the time of 131 I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 1440-1445.
19. Menéndez Torre E, López Carballo MT, Rodríguez Erdozáin RM, Forga Llenas L, Goñi Iriarte MJ, Barbería Layana JJ: Prognostic value of thyroglobulin serum levels and 131 I whole-body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid 2004; 14: 301-306. (Pubitemid 38569280)
20. Pacini F, Elisei R, Capezzone M, et al: Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low-and high-risk patients. Thyroid 2001; 11: 877-881. (Pubitemid 32847946)
21. Kumar H, Daykin J, Holder R, Watkinson JC, Sheppard MC, Franklyn JA: Gender, clinical findings, and serum thyrotropin measurements in the prediction of thyroid neoplasia in 1,005 patients presenting with thyroid enlargement and investigated by fine-needle aspiration cytology. Thyroid 1999; 9: 1105-1109.
22. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G: Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 2004; 11: 571-579. (Pubitemid 39331285)
23. Forest VI, Clark JR, Ebrahimi A, et al: Central compartment dissection in thyroid papillary carcinoma. Ann Surg 2011; 253: 123-130.
24. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM: Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 2010; 148: 1100-1106.
25. Wada N, Sugino K, Mimura T, et al: Pediatric differentiated thyroid carcinoma in stage I: risk factor analysis for disease free survival. BMC Cancer 2009; 9: 306.
26. Elisei R, Schlumberger M, Driedger A, et al: Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009; 94: 4171-4179.
27. Phan HT, Jager PL, van der Wal JE, et al: The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol 2008; 158: 77-83. (Pubitemid 351211043)
28. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, et al: Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92: 2610-2615. (Pubitemid 47037365)
29. Lin JD: Thyroglobulin and human thyroid cancer. Clin Chim Acta 2008; 388: 15-21.
30. Travagli JP, Cailleux AF, Ricard M, et al: Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 2675-2680. (Pubitemid 28493759)
31. Ito Y, Hirokawa M, Fukushima M, et al: Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg 2008; 32: 1535-1543.
32. Machens A, Hinze R, Lautenschläger C, Dralle H: Multivariate analysis of clinicopathologic parameters for the insular subtype of differentiated thyroid carcinoma. Arch Surg 2001; 136: 941-944. (Pubitemid 32729557)